Legal & General Group Plc Buys 25,338 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Legal & General Group Plc lifted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 27.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 116,959 shares of the company's stock after acquiring an additional 25,338 shares during the period. Legal & General Group Plc owned approximately 0.21% of Harmony Biosciences worth $4,025,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC lifted its stake in Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after purchasing an additional 965 shares during the last quarter. KBC Group NV lifted its stake in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after purchasing an additional 819 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Harmony Biosciences by 28.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after purchasing an additional 519 shares during the last quarter. Finally, Avanza Fonder AB bought a new position in Harmony Biosciences in the 4th quarter valued at approximately $145,000. Institutional investors own 86.23% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective for the company. Mizuho upped their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday, March 18th. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. UBS Group decreased their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday. Finally, Needham & Company LLC restated a "buy" rating and issued a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $52.44.

Harmony Biosciences Trading Down 0.8 %

Shares of HRMY traded down $0.25 during trading hours on Monday, hitting $29.36. 810,045 shares of the stock were exchanged, compared to its average volume of 579,383. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The business has a 50-day moving average of $31.84 and a 200-day moving average of $34.23. The firm has a market capitalization of $1.68 billion, a P/E ratio of 13.91, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $201.30 million during the quarter, compared to analysts' expectations of $201.25 million. During the same period in the prior year, the company posted $0.45 earnings per share. Harmony Biosciences's revenue for the quarter was up 19.5% compared to the same quarter last year. On average, research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.